State Street
JSPR icon

State Street’s Jasper Therapeutics JSPR Stock Holding History

State Street’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$39.2K Hold
44,699
– – ﹤0.01% 4161
2025
Q4 		$81.8K Hold
44,699
– – ﹤0.01% 4077
2025
Q3 		$106K Sell
44,699
-55
-0.1% -$167 ﹤0.01% 4042
2025
Q2 		$248K Sell
44,754
-183,122
-80% -$902K ﹤0.01% 3771
2025
Q1 		$980K Sell
227,876
-2,430
-1% -$16.2K ﹤0.01% 3430
2024
Q4 		$4.92M Buy
230,306
+15,423
+7% +$321K ﹤0.01% 2989
2024
Q3 		$4.04M Buy
214,883
+23,564
+12% +$469K ﹤0.01% 3062
2024
Q2 		$4.34M Buy
191,319
+151,320
+378% +$3.63M ﹤0.01% 2986
2024
Q1 		$1.17M Buy
39,999
+17,000
+74% +$302K ﹤0.01% 3429
2023
Q4 		$181K Hold
22,999
– – ﹤0.01% 3928
2023
Q3 		$161K Buy
22,999
+3,090
+16% +$37.7K ﹤0.01% 3990
2023
Q2 		$273K Hold
19,909
– – ﹤0.01% 3912
2023
Q1 		$360K Buy
19,909
+16,621
+506% +$307K ﹤0.01% 3858
2022
Q4 		$15.6K Hold
3,288
– – ﹤0.01% 4763
2022
Q3 		$26K Hold
3,288
– – ﹤0.01% 4787
2022
Q2 		$63K Buy
3,288
+1,113
+51% +$31.7K ﹤0.01% 4674
2022
Q1 		$77K Buy
+2,175
New +$98K ﹤0.01% 4708

Other funds holding JSPR

VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

State Street's JSPR Position: Q1 2026 in Review

State Street held its Jasper Therapeutics (JSPR) position steady in Q1 2026 at 44,699 shares worth $39.2K. The position accounts for ﹤0.01% of the portfolio, ranked #4161.

State Street first reported a position in JSPR in Q1 2022 and has held it in 17 quarters since. The position peaked at $4.92M in Q4 2024. 58 funds tracked by Wall St. Rank hold JSPR as of Q1 2026.

  • State Street held 44,699 shares of Jasper Therapeutics worth $39.2K as of Q1 2026.
  • State Street left its Jasper Therapeutics share count unchanged in Q1 2026.
  • Jasper Therapeutics made up ﹤0.01% of State Street's portfolio in Q1 2026, its #4161 holding.
  • State Street first reported a position in Jasper Therapeutics in Q1 2022 and has held it in 17 quarters since.
  • State Street's Jasper Therapeutics position peaked at $4.92M in Q4 2024.
  • 58 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.